Rafael Santana-Davila, MD

Rafael Santana-Davila, MD

Assistant Member
Clinical Research Division
Attending Physician
Seattle Cancer Care Alliance
Medical Director, Infusion and Pharmacy Services
Seattle Cancer Care Alliance

Education

Anahuac University School of Medicine, Mexico. M.D. Cum Laude
Research trainee, Mayo Clinic
Residency: Internal Medicine, University of Minnesota
Fellowship: Hematology and Oncology, Mayo Clinic College of Medicine

Research Focus

Research interests include health services research, where the main goal is to understand how patients are treated in the general population (who do not have access to cancer centers) and learning how the most recent advances might be brought to treating these individuals. Also working to design and implement clinical trials that might establish a new, life-saving treatment. Another recent focus is on strategies to harness the immune system in treating virus-associated cancers.

Clinical Expertise 

Dr. Santana-Davila is a medical oncologist who is board certified in Internal Medicine and in Hematology/Oncology. He specializes in treating patients with lung and head-and-neck cancers, and also has experience in treating patients with breast, gastric and hematologic cancers.

Clinical Trials

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)  

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) 

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) 

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL)  

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium  

Dose-escalation Study of anti-C4.4a antibody drug conjugate BAY1129980 in subjects with advanced solid tumors



Related News

Additional Links & Information

Related Labs & Projects

View all labs & projects >
Rafael Santana-Davila, MD

Contact Information

Phone
(206) 606-2190
Fax
(206) 606-1435
Email
Additional contact

Mail Stop: K2-231